医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

SYDNEY

Sirtex Medical Limited (ASX:SRX) today announced dose sales of its SIR-Spheres® microspheres targeted radiation therapy for liver cancer grew 13.1 per cent for the quarter ended 30 June 2013 compared to the previous corresponding period. For Financial Year 2013 dose sales of SIR-Spheres microspheres grew 19 per cent. Despite being off a higher base, the FY2013 result delivers continued strong dose sales growth following the 23 per cent growth in FY2012, 19 per cent growth in FY2011 and 14 per cent growth in FY2010.

Quarterly growth by region was solid with the Americas recording dose sales growth of 17 per cent, Asia Pacific grew by 21 per cent and Europe, Middle East and Africa (EMEA) increased one per cent. The full year growth rate by region resulted in the Americas growing by 21 per cent, Asia Pacific growing by 30 per cent and EMEA growing by 9 per cent.

Sirtex Chief Executive Officer Gilman Wong said, “This is the highest number of doses we have sold in a quarter adding to our successful history. We have now achieved 36 consecutive quarters of dose sales growth, which we expect to continue.”

“For longer term growth our focus remains on our 2020Vision strategy as we invest in and build our business to prepare Sirtex for the release of the results from the SIRFLOX clinical study, which are expected to be available towards the end of 2014,” Mr Wong said.

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.